{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:20:00Z","timestamp":1779272400945,"version":"3.51.4"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.neulet.2021.136064","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T05:30:25Z","timestamp":1623907825000},"page":"136064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["The endocannabinoid system as a therapeutic target for schizophrenia: Failures and potentials"],"prefix":"10.1016","volume":"759","author":[{"given":"Alexandre","family":"Seillier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neulet.2021.136064_b0005","doi-asserted-by":"crossref","first-page":"8342","DOI":"10.1002\/jcp.27725","article-title":"Medical Cannabis: A plurimillennial history of an evergreen","volume":"234","author":"Pisanti","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.neulet.2021.136064_b0010","first-page":"34","article-title":"Marijuana in medicine: past, present and future","volume":"110","author":"Mikuriya","year":"1969","journal-title":"Calif. Med."},{"key":"10.1016\/j.neulet.2021.136064_b0015","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1021\/ja01062a046","article-title":"Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish","volume":"86","author":"Gaoni","year":"1964","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.neulet.2021.136064_b0020","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","article-title":"Structure of a cannabinoid receptor and functional expression of the cloned cDNA","volume":"346","author":"Matsuda","year":"1990","journal-title":"Nature."},{"key":"10.1016\/j.neulet.2021.136064_b0025","doi-asserted-by":"crossref","unstructured":"W. Devane, L. Hanus, A. Breuer, R. Pertwee, L. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, R. Mechoulam, Isolation and structure of a brain constituent that binds to the cannabinoid receptor, Science (80-.). 258 (1992) 1946\u20131949. https:\/\/doi.org\/10.1126\/science.1470919.","DOI":"10.1126\/science.1470919"},{"key":"10.1016\/j.neulet.2021.136064_b0030","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","article-title":"An introduction to the endogenous cannabinoid system","volume":"79","author":"Lu","year":"2016","journal-title":"Biol. Psychiatry."},{"key":"10.1016\/j.neulet.2021.136064_b0035","first-page":"1483","article-title":"Cannabis and schizophrenia. A longitudinal study of Swedish conscripts Lancet (London, England)","volume":"2","author":"Andr\u00e9asson","year":"1987"},{"key":"10.1016\/j.neulet.2021.136064_b0040","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fpsyt.2014.00054","article-title":"Gone to Pot - A Review of the Association between Cannabis and Psychosis","volume":"5","author":"Radhakrishnan","year":"2014","journal-title":"Front. Psychiatry."},{"key":"10.1016\/j.neulet.2021.136064_b0045","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1017\/S0033291716003172","article-title":"Assessing causality in associations between cannabis use and schizophrenia risk: a two-sample Mendelian randomization study","volume":"47","author":"Gage","year":"2017","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neulet.2021.136064_b0050","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11920-015-0657-y","article-title":"Cannabis and Psychosis: a Critical Overview of the Relationship","volume":"18","author":"Ksir","year":"2016","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.neulet.2021.136064_b0055","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s13311-015-0382-6","article-title":"Cannabinoids and Schizophrenia: Risks and Therapeutic Potential","volume":"12","author":"Manseau","year":"2015","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.neulet.2021.136064_b0060","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0091-3057(96)00426-1","article-title":"Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system","volume":"56","author":"Emrich","year":"1997","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neulet.2021.136064_b0065","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1586\/14737175.8.7.1037","article-title":"Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia","volume":"8","author":"M\u00fcller-Vahl","year":"2008","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neulet.2021.136064_b0070","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","article-title":"Meta-Trial Study Group, Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder","volume":"161","author":"Meltzer","year":"2004","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.neulet.2021.136064_b0075","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrendo.2009.197","article-title":"CB1 antagonists for obesity\u2013what lessons have we learned from rimonabant?","volume":"5","author":"Di Marzo","year":"2009","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.neulet.2021.136064_b0080","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/JCP.0b013e3181a6bc3b","article-title":"Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia","volume":"29","author":"Schwarcz","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neulet.2021.136064_b0085","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2174\/1574889810999160603185126","article-title":"Beyond the Direct Activation of Cannabinoid Receptors: New Strategies to Modulate the Endocannabinoid System in CNS-Related Diseases","volume":"10","author":"Chicca","year":"2016","journal-title":"Recent Pat. CNS Drug Discov."},{"key":"10.1016\/j.neulet.2021.136064_b0090","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrd.2018.115","article-title":"New approaches and challenges to targeting the endocannabinoid system","volume":"17","author":"Di Marzo","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neulet.2021.136064_b0095","doi-asserted-by":"crossref","first-page":"498","DOI":"10.5414\/CP202687","article-title":"FAAH inhibitors in the limelight, but regrettably","volume":"54","author":"Mallet","year":"2016","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neulet.2021.136064_b0100","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.euroneuro.2020.01.013","article-title":"Possible therapeutic applications of cannabis in the neuropsychopharmacology field","volume":"36","author":"Fern\u00e1ndez-Ruiz","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neulet.2021.136064_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12888-019-2409-8","article-title":"Medicinal cannabis for psychiatric disorders: A clinically-focused systematic review","volume":"20","author":"Sarris","year":"2020","journal-title":"BMC Psychiatry."},{"key":"10.1016\/j.neulet.2021.136064_b0110","doi-asserted-by":"crossref","DOI":"10.1177\/2045125319881916","article-title":"Cannabidiol as a potential treatment for psychosis","volume":"9","author":"Davies","year":"2019","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.neulet.2021.136064_b0115","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pnpbp.2012.04.002","article-title":"New insights on endocannabinoid transmission in psychomotor disorders","volume":"38","author":"Giuffrida","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry."},{"key":"10.1016\/j.neulet.2021.136064_b0120","unstructured":"J.-J. Moreau, Du Hachisch et de l\u2019Alienation Mentale: Etudes Psychologiques., Paris\u00a0: Fortin, Masson, 1845."},{"key":"10.1016\/j.neulet.2021.136064_b0125","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.3389\/fimmu.2018.02009","article-title":"Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age","volume":"9","author":"Crippa","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neulet.2021.136064_b0130","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF00432554","article-title":"Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects","volume":"76","author":"Zuardi","year":"1982","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.neulet.2021.136064_b0135","first-page":"485","article-title":"Antipsychotic effect of cannabidiol","volume":"56","author":"Zuardi","year":"1995","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.neulet.2021.136064_b0140","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1177\/0269881106060967","article-title":"Cannabidiol monotherapy for treatment-resistant schizophrenia","volume":"20","author":"Zuardi","year":"2006","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neulet.2021.136064_b0145","first-page":"262","article-title":"Remission of severe, treatment-resistant schizophrenia following adjunctive cannabidiol., Aust. N. Z","volume":"53","author":"Makiol","year":"2019","journal-title":"J Psychiatry."},{"key":"10.1016\/j.neulet.2021.136064_b0150","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry."},{"key":"10.1016\/j.neulet.2021.136064_b0155","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/S0920-9964(14)70153-7","article-title":"Modulation of the Endocannabinoid System As a Potential New Target in the Treatment of Schizophrenia","volume":"153","author":"Leweke","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neulet.2021.136064_b0160","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","article-title":"Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial","volume":"175","author":"McGuire","year":"2018","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.neulet.2021.136064_b0165","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","article-title":"The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial","volume":"235","author":"Boggs","year":"2018","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.neulet.2021.136064_b0170","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1590\/S1516-44462010000100011","article-title":"Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)","volume":"32","author":"Hallak","year":"2010","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.neulet.2021.136064_b0175","first-page":"1","article-title":"Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis","author":"O\u2019Neill","year":"2020","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neulet.2021.136064_b0180","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","article-title":"Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis","volume":"6","author":"Black","year":"2019","journal-title":"The Lancet. Psychiatry."},{"key":"10.1016\/j.neulet.2021.136064_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.112890","article-title":"Cannabidiol for the treatment of psychosis among patients with schizophrenia and other primary psychotic disorders: A systematic review with a risk of bias assessment","volume":"286","author":"Ghabrash","year":"2020","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.neulet.2021.136064_b0190","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s13311-015-0377-3","article-title":"Molecular Targets of Cannabidiol in Neurological Disorders","volume":"12","author":"Ibeas Bih","year":"2015","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.neulet.2021.136064_b0195","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bph.12944","article-title":"Are cannabidiol and \u0394(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review","volume":"172","author":"McPartland","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neulet.2021.136064_b0200","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","article-title":"Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro","volume":"150","author":"Thomas","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neulet.2021.136064_b0205","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neulet.2021.136064_b0210","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3389\/fphar.2017.00744","article-title":"Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB2 Receptors","volume":"8","author":"Mart\u00ednez-Pinilla","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neulet.2021.136064_b0215","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40263-018-0539-z","article-title":"Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention","volume":"32","author":"Leweke","year":"2018","journal-title":"CNS Drugs."},{"key":"10.1016\/j.neulet.2021.136064_b0220","doi-asserted-by":"crossref","first-page":"8711","DOI":"10.1074\/jbc.M114.618447","article-title":"Fatty acid-binding proteins (FABPs) are intracellular carriers for \u03949-tetrahydrocannabinol (THC) and cannabidiol (CBD)","volume":"290","author":"Elmes","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neulet.2021.136064_b0225","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","article-title":"Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes","volume":"163","author":"De Petrocellis","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neulet.2021.136064_b0230","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1248\/bpb.19.1109","article-title":"Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids","volume":"19","author":"Watanabe","year":"1996","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.neulet.2021.136064_b0235","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neulet.2021.136064_b0240","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1089\/can.2018.0031","article-title":"Cannabidiol\u2019s Upregulation of N-acyl Ethanolamines in the Central Nervous System Requires N-acyl Phosphatidyl Ethanolamine-Specific Phospholipase D","volume":"3","author":"Leishman","year":"2018","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.neulet.2021.136064_b0245","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1111\/bcp.14038","article-title":"A systematic review of cannabidiol dosing in clinical populations","volume":"85","author":"Millar","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neulet.2021.136064_b0250","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01365","article-title":"A systematic review on the pharmacokinetics of cannabidiol in humans","volume":"9","author":"Millar","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neulet.2021.136064_b0255","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1001\/archpsyc.58.4.322","article-title":"Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716","volume":"58","author":"Huestis","year":"2001","journal-title":"Arch. Gen. Psychiatry."},{"key":"10.1016\/j.neulet.2021.136064_b0260","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1097\/00001756-199906030-00008","article-title":"Elevated endogenous cannabinoids in schizophrenia","volume":"10","author":"Leweke","year":"1999","journal-title":"Neuroreport."},{"key":"10.1016\/j.neulet.2021.136064_b0265","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0306-4522(00)00552-2","article-title":"Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use","volume":"103","author":"Dean","year":"2001","journal-title":"Neuroscience."},{"key":"10.1016\/j.neulet.2021.136064_b0270","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/JCP.0b013e318204825b","article-title":"Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study","volume":"31","author":"Kelly","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neulet.2021.136064_b0275","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.schres.2011.11.009","article-title":"Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial","volume":"134","author":"Boggs","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neulet.2021.136064_b0280","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000122763","article-title":"Psychosis following anti-obesity treatment with rimonabant","volume":"1","author":"Ugur","year":"2008","journal-title":"Obes. Facts."},{"key":"10.1016\/j.neulet.2021.136064_b0285","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1574889809666140307115532","article-title":"Therapeutic potential of cannabinoids in schizophrenia","volume":"9","author":"Kucerova","year":"2014","journal-title":"Recent Pat. CNS Drug Discov."},{"key":"10.1016\/j.neulet.2021.136064_b0290","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00213-009-1506-7","article-title":"The future of endocannabinoid-oriented clinical research after CB1 antagonists","volume":"205","author":"Le Foll","year":"2009","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.neulet.2021.136064_b0295","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.2174\/1568026619666190708164841","article-title":"Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development","volume":"19","author":"Nguyen","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.neulet.2021.136064_b0300","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.drudis.2010.04.004","article-title":"How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue","volume":"15","author":"Giraldo","year":"2010","journal-title":"Drug Discov. Today."},{"key":"10.1016\/j.neulet.2021.136064_b0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21082778","article-title":"A guide to targeting the endocannabinoid system in drug design","volume":"21","author":"Stasiulewicz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neulet.2021.136064_b0310","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.schres.2012.07.021","article-title":"Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia","volume":"141","author":"Jenko","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neulet.2021.136064_b0315","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.schres.2014.07.017","article-title":"Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia","volume":"159","author":"Volk","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neulet.2021.136064_b0320","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00213-009-1608-2","article-title":"Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment","volume":"206","author":"Urig\u00fcen","year":"2009","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.neulet.2021.136064_b0325","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/archpsyc.65.7.772","article-title":"Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia","volume":"65","author":"Eggan","year":"2008","journal-title":"Arch. Gen. Psychiatry."},{"key":"10.1016\/j.neulet.2021.136064_b0330","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1177\/0269881119857205","article-title":"Endocannabinoid system imbalance in the postmortem prefrontal cortex of subjects with schizophrenia","volume":"33","author":"Muguruza","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neulet.2021.136064_b0335","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/npp.2011.43","article-title":"Paranoid schizophrenia is characterized by increased CB 1 receptor binding in the dorsolateral prefrontal cortex","volume":"36","author":"Dalton","year":"2011","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.neulet.2021.136064_b0340","article-title":"Endocannabinoid system in psychotic and mood disorders, a review of human studies","author":"Garani","year":"2020","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry."},{"key":"10.1016\/j.neulet.2021.136064_b0345","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00406-002-0366-5","article-title":"Cannabis and schizophrenia: Impact on onset, course, psychopathology and outcomes","volume":"252","author":"Bersani","year":"2002","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.neulet.2021.136064_b0350","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.jpsychires.2012.04.019","article-title":"Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders","volume":"46","author":"Koola","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neulet.2021.136064_b0355","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jamapsychiatry.2013.3726","article-title":"Comorbidity of severe psychotic disorders with measures of substance use","volume":"71","author":"Hartz","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neulet.2021.136064_b0360","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.schres.2004.01.005","article-title":"Lower negative symptom scores among cannabis-dependent patients with schizophrenia-spectrum disorders: Preliminary evidence from an African American first-episode sample","volume":"71","author":"Compton","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neulet.2021.136064_b0365","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.schres.2006.05.006","article-title":"Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction","volume":"86","author":"Dubertret","year":"2006","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neulet.2021.136064_b0370","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1600-0447.1992.tb01456.x","article-title":"Influence of cannabis abuse on schizophrenic psychopathology","volume":"85","author":"Peralta","year":"1992","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.neulet.2021.136064_b0375","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.schres.2011.02.017","article-title":"The effects of cannabis use on neurocognition in schizophrenia: A meta-analysis","volume":"128","author":"Rabin","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neulet.2021.136064_b0380","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/schbul\/sbq079","article-title":"The impact of cannabis use on cognitive functioning in patients with schizophrenia: A meta-analysis of existing findings and new data in a first-episode sample","volume":"38","author":"Y\u00fccel","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neulet.2021.136064_b0385","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/0269881117735684","article-title":"Medicinal cannabis (Bedrolite) substitution therapy in inpatients with a psychotic disorder and a comorbid cannabis use disorder: A case series","volume":"32","author":"Schipper","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neulet.2021.136064_b0390","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.biopsych.2004.12.006","article-title":"Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction","volume":"57","author":"D\u2019Souza","year":"2005","journal-title":"Biol. Psychiatry."},{"key":"10.1016\/j.neulet.2021.136064_b0395","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.schres.2014.04.033","article-title":"Impaired functional connectivity of brain reward circuitry in patients with schizophrenia and cannabis use disorder: Effects of cannabis and THC","volume":"158","author":"Fischer","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neulet.2021.136064_b0400","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0925-4927(01)00104-4","article-title":"Cannabis induced dopamine release: an in-vivo SPECT study","volume":"107","author":"Voruganti","year":"2001","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.neulet.2021.136064_b0405","first-page":"1","article-title":"Synthetic cannabinoid induced ocular self-injury","volume":"00","author":"Malik","year":"2020","journal-title":"Orbit (London)."},{"key":"10.1016\/j.neulet.2021.136064_b0410","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S2215-0366(15)00363-6","article-title":"Continued versus discontinued cannabis use in patients with psychosis: A systematic review and meta-analysis","volume":"3","author":"Schoeler","year":"2016","journal-title":"The Lancet Psychiatry."},{"key":"10.1016\/j.neulet.2021.136064_b0415","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.neubiorev.2020.07.007","article-title":"Cannabis, nicotine and the negative symptoms of schizophrenia: Systematic review and meta-analysis of observational studies","volume":"116","author":"Sabe","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neulet.2021.136064_b0420","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4103\/0976-500X.189661","article-title":"What failed BIA 10\u20132474 Phase I clinical trial? Global speculations and recommendations for future Phase I trials","volume":"7","author":"Kaur","year":"2016","journal-title":"J. Pharmacol. Pharmacother."},{"key":"10.1016\/j.neulet.2021.136064_b0425","doi-asserted-by":"crossref","unstructured":"A.C.M. Van Esbroeck, A.P.A. Janssen, A.B. Cognetta, D. Ogasawara, G. Shpak, M. Van Der Kroeg, V. Kantae, M.P. Baggelaar, F.M.S. De Vrij, H. Deng, M. Allar\u00e0, F. Fezza, Z. Lin, T. Van Der Wel, M. Soethoudt, E.D. Mock, H. Den Dulk, I.L. Baak, B.I. Florea, G. Hendriks, L. De Petrocellis, H.S. Overkleeft, T. Hankemeier, C.I. De Zeeuw, V. Di Marzo, M. Maccarrone, B.F. Cravatt, S.A. Kushner, M. Van Der Stelt, Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474, Science (80-.). 356 (2017) 1084\u20131087. https:\/\/doi.org\/10.1126\/science.aaf7497.","DOI":"10.1126\/science.aaf7497"},{"key":"10.1016\/j.neulet.2021.136064_b0430","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.biopsych.2009.09.024","article-title":"Brain Cannabinoid CB2 Receptor in Schizophrenia","volume":"67","author":"Ishiguro","year":"2010","journal-title":"Biol. Psychiatry."},{"key":"10.1016\/j.neulet.2021.136064_b0435","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.3390\/ph3082517","article-title":"Brain CB2 receptors: Implications for neuropsychiatric disorders","volume":"3","author":"Roche","year":"2010","journal-title":"Pharmaceuticals."},{"key":"10.1016\/j.neulet.2021.136064_b0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpsyt.2020.00046","article-title":"Inflammation and Negative Symptoms of Schizophrenia: Implications for Reward Processing and Motivational Deficits","volume":"11","author":"Goldsmith","year":"2020","journal-title":"Front. Psychiatry."},{"key":"10.1016\/j.neulet.2021.136064_b0445","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nn.3053","article-title":"Mitochondrial CB 1 receptors regulate neuronal energy metabolism","volume":"15","author":"B\u00e9nard","year":"2012","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neulet.2021.136064_b0450","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nature20127","article-title":"A cannabinoid link between mitochondria and memory","volume":"539","author":"Hebert-Chatelain","year":"2016","journal-title":"Nature."},{"key":"10.1016\/j.neulet.2021.136064_b0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bies.201700126","article-title":"Linking Mitochondria and Synaptic Transmission: The CB1 Receptor","volume":"39","author":"Djeungoue-Petga","year":"2017","journal-title":"BioEssays."},{"key":"10.1016\/j.neulet.2021.136064_b0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bies.201900202","article-title":"Mitochondrial Dysfunction in Schizophrenia","volume":"42","author":"Ni","year":"2020","journal-title":"BioEssays."},{"key":"10.1016\/j.neulet.2021.136064_b0465","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/glia.23314","article-title":"Localization of the cannabinoid type-1 receptor in subcellular astrocyte compartments of mutant mouse hippocampus","volume":"66","author":"Guti\u00e9rrez-Rodr\u00edguez","year":"2018","journal-title":"Glia."},{"key":"10.1016\/j.neulet.2021.136064_b0470","doi-asserted-by":"crossref","first-page":"259","DOI":"10.31887\/DCNS.2020.22.3\/vdimarzo","article-title":"The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders","volume":"22","author":"Di Marzo","year":"2020","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.neulet.2021.136064_b0475","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41401-018-0164-x","article-title":"Translational potential of allosteric modulators targeting the cannabinoid CB 1 receptor","volume":"40","author":"Lu","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.neulet.2021.136064_b0480","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.4155\/fmc-2019-0005","article-title":"Allosteric modulators targeting cannabinoid cb1 and cb2 receptors: Implications for drug discovery","volume":"11","author":"Gado","year":"2019","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.neulet.2021.136064_b0485","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bcp.2018.07.031","article-title":"Emerging strategies targeting CB2 cannabinoid receptor: Biased agonism and allosterism","volume":"157","author":"Morales","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neulet.2021.136064_b0490","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/cpt.1381","article-title":"Positive and Negative Effects of Cannabis and Cannabinoids on Health","volume":"105","author":"Cohen","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neulet.2021.136064_b0495","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.2217\/nnm-2020-0221","article-title":"Challenges of cannabinoid delivery: How can nanomedicine help?","volume":"15","author":"Onaivi","year":"2020","journal-title":"Nanomedicine."},{"key":"10.1016\/j.neulet.2021.136064_b0500","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/17425247.2020.1762563","article-title":"Nose-to-brain delivery of antipsychotics using nanotechnology: a review","volume":"17","author":"Tan","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.neulet.2021.136064_b0505","article-title":"Can precision medicine advance psychiatry?","author":"Roche","year":"2020","journal-title":"Ir. J. Psychol. Med."},{"key":"10.1016\/j.neulet.2021.136064_b0510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13318-017-0416-z","article-title":"Pharmacogenetics of Cannabinoids","volume":"43","author":"Hryhorowicz","year":"2018","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.neulet.2021.136064_b0515","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.biopsych.2016.01.004","article-title":"Changes in cannabis potency over the last 2 decades (1995\u20132014): Analysis of current data in the United States","volume":"79","author":"ElSohly","year":"2016","journal-title":"Biol. Psychiatry."},{"key":"10.1016\/j.neulet.2021.136064_b0520","first-page":"31","article-title":"Synthetic cannabinoids\u2014 \u201dspice\u201d can induce a psychosis: A brief review","volume":"16","author":"Yeruva","year":"2019","journal-title":"Innov. Clin. Neurosci."},{"key":"10.1016\/j.neulet.2021.136064_b0525","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.clinthera.2018.08.002","article-title":"Therapeutic Use of Synthetic Cannabinoids: Still an OpenIssue?","volume":"40","author":"De Luca","year":"2018","journal-title":"Clin. Ther."}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394021004420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394021004420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T20:43:08Z","timestamp":1759610588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394021004420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":105,"alternative-id":["S0304394021004420"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2021.136064","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The endocannabinoid system as a therapeutic target for schizophrenia: Failures and potentials","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2021.136064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"136064"}}